Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.
Maud B A van der KleijNiels A D GuchelaarMarinda MeertensKim WesterdijkEline L GiraudRoos F BleckmanStefanie L GroenlandRuben A G van EerdenAlex L T ImholzAnnelie J E VulinkHans-Martin OttenHelle-Brit Fiebrich-WestraFloor J E LubbermanIngrid M E DesarDirk Jan A R MoesDaan J TouwStijn L W KoolenHans GelderblomAnna K L ReynersNielka P van ErpRon H J MathijssenAlwin D R Huitemanull nullNeeltje SteeghsPublished in: British journal of cancer (2024)
Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions.